ARTICLE | Emerging Company Profile
Mycovia tackling chronic infections with antifungal pipeline
Mycovia aims to treat chronic fungal infections with safer CYP51 inhibitors
November 11, 2019 7:55 PM UTC
Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections.
The company's lead product VT-1161 otesaconazole is in Phase III testing for recurrent vulvovaginal candidiasis (rVVC), a chronic yeast infection that affects about 138 million women worldwide every year. ...
BCIQ Company Profiles